Completing the CE Mark submission for Eversense 365 brings us a step closer to improving lives and health outcomes for ...

Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

The US FDA warns users of smartphone-linked diabetes devices like CGMs and insulin pumps of potential health risks due to ...

Artificial intelligence (AI) is transforming dietary management for diabetes and obesity, offering personalized nutrition plans, real-time glucose mon.

US FDA alerts patients of potential to miss critical safety alerts due to phone settings when using smartphone-compatible diabetes devices: Maryland Friday, February 7, 2025, 09:0 ...

Health-related technologies have evolved significantly in the modern world, offering people innovative tools to manage their ...

Gonzaga University and the UW School of Medicine hosted Irl Hirsch to lecture about the future of glucose monitoring.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can predict microvascular diabetes complications similarly to glycated hemoglobin.

Devices and Getinge have recently announced their partnership under which they will integrate Getinge’s bioreactors with 908 ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq ...

Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...